Deutsche Bank Thinks Eli Lilly & Co’s Stock is Going to Recover

In a report issued on March 24, Gregg Gilbert from Deutsche Bank maintained a Buy rating on Eli Lilly & Co (NYSE: LLY), with a price target of $99. The company’s shares closed last Thursday at $71.12, close to its 52-week low of $67.88.

Currently, the analyst consensus on Eli Lilly & Co is Strong Buy and the average price target is $100, representing a 40.6% upside. In a report issued on March 15, Jefferies also maintained a Buy rating on the stock with a $105 price target.

The company has a one year high of $91.63 and a one year low of $67.88. Currently, Eli Lilly & Co has an average volume of 5.4M.

Unlike Deutsche Bank`s latest rating, based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2015, Susan Mahony, a the SVP & Pres., Lilly Oncology of LLY sold 25,000 shares for a total of $2,124,000.

According to, Gilbert is a 1-star analyst with an average return of -2.6% and a 35.6% success rate. Gilbert covers the Healthcare sector, focusing on stocks such as Amag Pharmaceuticals, Jazz Pharmaceuticals, and Endo International.

Eli Lilly and Co is a drug manufacturing company. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.